MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Acura Pharmaceuticals Company Profile (NASDAQ:ACUR)

Consensus Ratings for Acura Pharmaceuticals (NASDAQ:ACUR) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (220.86% upside)

Analysts' Ratings History for Acura Pharmaceuticals (NASDAQ:ACUR)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016Roth CapitalReiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015MLV & Co.Initiated CoverageBuy$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Acura Pharmaceuticals (NASDAQ:ACUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
5/2/2016Q116($0.26)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q315($0.03)($0.08)$2.70 million$2.68 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q215($0.02)($0.05)$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115$0.07$0.03$7.60 million$5.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.09)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014($0.08)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014($0.08)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014($0.05)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q4 13($0.06)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2013Q4 2012($0.86)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Acura Pharmaceuticals (NASDAQ:ACUR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.20)($0.20)($0.20)
Q2 20162($0.28)($0.27)($0.28)
Q3 20162($0.28)($0.18)($0.23)
Q4 20162($0.28)($0.20)($0.24)
(Data provided by Zacks Investment Research)
Dividend History for Acura Pharmaceuticals (NASDAQ:ACUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Acura Pharmaceuticals (NASDAQ:ACUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/17/2015Claudius LlcMajor ShareholderSell104,823$1.08$113,208.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Claudius LlcMajor ShareholderSell171,000$0.62$106,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014William G SkellyDirectorSell4,600$1.23$5,658.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014William G SkellyDirectorSell5,000$1.21$6,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Albert W BrzeczkoVPBuy2,000$1.20$2,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Bruce F WessonDirectorBuy80,000$1.13$90,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014James F EmighVPBuy15,000$1.21$18,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Peter A ClemensCFOBuy3,000$1.21$3,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014William G SkellyDirectorSell2,900$1.21$3,509.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014William G SkellyDirectorSell5,000$1.25$6,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014William G SkellyDirectorSell2,500$1.30$3,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Claudius LlcMajor ShareholderSell2,500$2.00$5,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2014Claudius LlcMajor ShareholderSell351,260$2.02$709,545.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014Claudius LlcMajor ShareholderSell44,019$1.97$86,717.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Albert W BrzeczkoVPBuy1,215$1.70$2,065.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Claudius LlcMajor ShareholderSell4,200$2.05$8,610.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2013William G SkellyDirectorSell2,000$1.55$3,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Care Capital Ii LlcMajor ShareholderSell31,610$2.04$64,484.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Care Capital Ii LlcMajor ShareholderSell14,200$2.00$28,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Claudius LlcMajor ShareholderSell200,000$2.15$430,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Care Capital Ii LlcMajor ShareholderSell76,281$2.01$153,324.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2013Care Capital Ii LlcMajor ShareholderSell83,000$2.03$168,490.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Care Capital Ii LlcMajor ShareholderSell114,000$2.12$241,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Claudius LlcMajor ShareholderSell20,446$2.15$43,958.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Care Capital Ii LlcMajor ShareholderSell90,000$2.16$194,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Care Capital Ii LlcMajor ShareholderSell102,000$2.19$223,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013Claudius LlcMajor ShareholderSell21,496$2.20$47,291.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013Claudius LlcMajor ShareholderSell39,453$2.19$86,402.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Care Capital Ii LlcMajor ShareholderSell148,000$2.24$331,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Claudius LlcMajor ShareholderSell31,559$2.25$71,007.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Care Capital Ii LlcMajor ShareholderSell108,701$2.33$253,273.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013William G SkellyDirectorSell2,000$2.40$4,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Care Capital Ii LlcMajor ShareholderSell252,000$2.31$582,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013William G SkellyDirectorSell4,000$2.33$9,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Claudius LlcMajor ShareholderSell47,410$2.30$109,043.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Care Capital Ii LlcMajor ShareholderSell510,000$2.36$1,203,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Care Capital Ii LlcMajor ShareholderSell662,000$2.38$1,575,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013William G SkellyDirectorSell3,000$2.25$6,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Claudius LlcMajor ShareholderSell183,434$2.33$427,401.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Care Capital Ii LlcMajor ShareholderSell259,000$2.19$567,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013William G SkellyDirectorSell3,000$2.20$6,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2013Claudius LlcMajor ShareholderSell121,454$2.23$270,842.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Care Capital Ii LlcMajor ShareholderSell39,554$2.17$85,832.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Acura Pharmaceuticals (NASDAQ:ACUR)
DateHeadline
06/26/16 07:06 AMAcura Pharmaceuticals Incorporated (NASDAQ:ACUR) Shorted Shares Increased By 60.19% - Engelwood Daily
06/24/16 10:17 AMAcura Pharmaceuticals, Inc. (ACUR) Updated Price Targets - FTSE News
06/15/16 07:23 PMAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Accounts Payable Is $0.375 For The Quarter Ended 2016-03-31 - RealistInvestor.com
06/13/16 02:19 PMBest Stocks: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), Nokia Corporation (ADR) (NYSE:NOK), Facebook Inc ... - KC Register
06/11/16 10:30 AMPre-Open Stock Movers 06/09: (ACUR) (CBK) (RADA) Higher; (RH) (INSM) (TMH) Lower (more...)
06/10/16 10:42 AMAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) plummeted -6.88%: Spartan Motors Inc. (NASDAQ:SPAR), Illumina Inc ... - KC Register
06/10/16 10:42 AMAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Reports Successful Clinical Trials For AP-LTX-400 - Journal Transcript
06/08/16 08:25 PMCompany Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc's LIMITX(TM) Technology Successfully Confirms Oral ... - Smarter Analyst
06/08/16 03:38 PMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib -
06/08/16 03:28 PMAcura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities - [at noodls] - June 8, 2016 PALATINE, IL -- (Marketwired) -- 06/08/16 -- Acura Pharmaceuticals, Inc.(NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results ...
06/06/16 02:20 PMAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Has $2.32 Millions Outstanding Debt Accrued - RealistInvestor.com
06/01/16 10:39 AMAcura Pharmaceuticals, Inc. (ACUR) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Acura Pharmaceuticals, Inc. (ACUR) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Acura Pharmaceuticals, Inc. (ACUR). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, 0 analysts ...Acura Pharmaceuticals Incorporated (NASDAQ:ACUR) Sellers Covered 14.5% of Their ShortsFranklin Independentall 2 news articles »
05/31/16 02:17 PMAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Set To Release Quarterly Earnings - Investor Newswire - Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) Set To Release Quarterly EarningsInvestor NewswireAccording to a group of market experts surveyed by Zacks Research, Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is projected to report earnings of $-0.24 for its recent quarter. The company plans to release its quarterly report on or around 2016-08-01.and more »
05/28/16 11:57 AMAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Quarterly EPS From Continuing Operations Stands At $-0.2828 - Investor Newswire - Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) Quarterly EPS From Continuing Operations Stands At $-0.2828Investor NewswireAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) diluted EPS from parent firm came at $-0.4621 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it came at $-0.4621. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) posted net basic EPS of ...
05/23/16 03:43 PMETF’s with exposure to Acura Pharmaceuticals, Inc. : May 23, 2016 -
05/11/16 10:10 AMAcura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/02/16 03:40 PMAcura Pharmaceuticals Announces First Quarter 2016 Financial Results - [at noodls] - May 2, 2016 PALATINE, IL -- (Marketwired) -- 05/02/16 -- Acura Pharmaceuticals, Inc.(NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results ...
05/02/16 06:07 AMQ1 2016 Acura Pharmaceuticals Inc Earnings Release - After Market Close -
04/28/16 03:53 PMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
04/28/16 05:28 AMIndiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemming State Meth Problem - [at noodls] - April 28, 2016 CULVER, IN -- (Marketwired) -- 04/28/16 -- Acura Pharmaceuticals, Inc.(NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced that, today, Indiana ...
04/26/16 03:36 PMAcura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology - [at noodls] - April 26, 2016 PALATINE, IL -- (Marketwired) -- 04/26/16 -- Acura Pharmaceuticals, Inc.(NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company ...
04/21/16 03:21 PMAcura Pharmaceuticals to Host First Quarter 2016 Financial Results Conference Call on May 3, 2016 - [at noodls] - April 21, 2016 PALATINE, IL -- (Marketwired) -- 04/21/16 -- Acura Pharmaceuticals, Inc.(NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company ...
03/30/16 03:21 PMAcura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective - [at noodls] - March 30, 2016 PALATINE, IL -- (Marketwired) -- 03/30/16 -- Acura Pharmaceuticals, Inc.(NASDAQ: ACUR)today announced that its universal shelf registration statement on Form S-3, as amended, was declared ...
03/28/16 08:35 AMETF’s with exposure to Acura Pharmaceuticals, Inc. : March 28, 2016 -
03/19/16 01:58 PMAcura Pharmaceuticals, Inc. (ACUR) New Analyst Updates - Risers & Fallers - Acura Pharmaceuticals, Inc. (ACUR) New Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Acura Pharmaceuticals, Inc. (ACUR). According to the latest broker reports outstanding on Thursday 17th of March, 1 analyst has a rating of “strong buy”, 1 analysts ...and more »
03/15/16 12:14 PMAcura Pharmaceuticals Acknowledges Inclusion of Meth-Resistant Technology in Indiana Legislation - About Acura Pharmaceuticals Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) is a specialty pharmaceutical company dedicated to bringing safe and effective products intended to address medication abuse and misuse to market. Acura is committed to addressing the ...
03/11/16 03:06 PMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
03/08/16 03:10 PMAcura Pharmaceuticals to Present at the 28th Annual ROTH Conference - [Marketwired] - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, ...
03/07/16 11:07 AMAcura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/06/16 01:50 PMRecent Broker Updates On Acura Pharmaceuticals, Inc. (ACUR) - Risers & Fallers - Recent Broker Updates On Acura Pharmaceuticals, Inc. (ACUR)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Acura Pharmaceuticals, Inc. (ACUR). The latest broker reports which are currently outstanding on Friday 4th of March state 1 analyst has a rating of “strong buy”, 0 ...Analysts Release New Consensus Estimates for Acura Pharmaceuticals (NASDAQ:ACUR)Hints News Networkall 3 news articles »
03/06/16 01:50 PMAnticipated EPS Increase for Acura Pharmaceuticals, Inc. (ACUR) - Stock Caller - Anticipated EPS Increase for Acura Pharmaceuticals, Inc. (ACUR)Stock CallerWall Street await Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) to release earnings on March, 7. Analysts forecast earnings per share of $-0.03, up exactly $0.27 or 90.00% from 2014's $-0.3 EPS. After releasing $-0.23 EPS for the previous quarter, Acura ...
02/29/16 03:30 PMAcura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results - [Marketwired] - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the year and three months ended December 31, 2015. The Company reported ...
02/29/16 06:07 AMQ4 2015 Acura Pharmaceuticals Inc Earnings Release - After Market Close -
02/28/16 01:20 PMAcura Pharmaceuticals Incorporated (NASDAQ:ACUR) Sellers Increased By 12.55% Their Shorts - RiversideGazette.com - Acura Pharmaceuticals Incorporated (NASDAQ:ACUR) Sellers Increased By 12.55% Their ShortsRiversideGazette.comThe short interest to Acura Pharmaceuticals Incorporated's float is 0.55%. The stock increased 1.94% or $0.04 on February 26, hitting $2.1. About 5,379 shares traded hands. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) has declined 49.27% since July 23, ...Analysts Release New Consensus Estimates for Acura PharmaceuticalsHints News Networkall 7 news articles »
02/28/16 01:20 PMCurrent Price Targets On Acura Pharmaceuticals, Inc. (ACUR) - Risers & Fallers - Current Price Targets On Acura Pharmaceuticals, Inc. (ACUR)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Acura Pharmaceuticals, Inc. (ACUR). The latest broker reports which are currently outstanding on Friday 26th of February state 1 analyst has a rating of “strong buy”, 0 ...
02/28/16 01:20 PMAnalysts See Rise of Acura Pharmaceuticals, Inc. (ACUR) EPS - OctaFinance.com - Analysts See Rise of Acura Pharmaceuticals, Inc. (ACUR) EPSOctaFinance.comAnalysts await Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) to reports earnings on February, 29 after the close. They expect $-0.03 EPS, up 90.00 % or $0.27 from last year's $-0.3 per share. After $-0.23 actual EPS reported by Acura Pharmaceuticals, Inc ...
02/24/16 02:03 PMAcura Pharmaceuticals, Inc. Company Profile - Acura Pharmaceuticals is working to provide accurate drug dosages without allowing for abuse. The company has developed a technology to add abuse-deterring agents to commonly abused pharmaceuticals. If a drug with these agents (what Acura calls Aversion ...
02/22/16 01:43 PMAcura Pharmaceuticals Inc.: Acura Pharmaceuticals to Host 2015 Financial Results Conference Call on March 1, 2016 - The Wall Street Transcript - Acura Pharmaceuticals Inc.: Acura Pharmaceuticals to Host 2015 Financial Results Conference Call on March 1, 2016The Wall Street TranscriptPALATINE, IL -- (Marketwired) -- 02/22/16 -- Acura Pharmaceuticals, Inc.(NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2015 following the ...and more »
02/22/16 05:30 AMAcura Pharmaceuticals to Host 2015 Financial Results Conference Call on March 1, 2016 - [Marketwired] - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2015 following the close of financial ...
02/19/16 01:23 PMPrice Target Update On Acura Pharmaceuticals, Inc. (ACUR) - Risers & Fallers - Price Target Update On Acura Pharmaceuticals, Inc. (ACUR)Risers & Fallers06/17/2015 – Acura Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 2 price target on the stock. 01/09/2015 – Acura Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Roth Capital ...Acura Pharmaceuticals Incorporated (NASDAQ:ACUR) Short Interest Decreased By 9.19%Clinton Financialall 2 news articles »
02/19/16 01:23 PMAcura Pharmaceuticals, Inc. (ACUR) - * = Where indicated, some values are estimates. 1 = Potential proceeds estimated by the filer. 2 = Estimated based on the average of multiple prices reported. 3 = Multiple dates reported. Most recent date shown. Currency in USD.
02/17/16 12:47 PMAcura Pharmaceuticals, Inc Bearish Trade. Flynn James E decreased Its Position - fdanewsalert.com - Acura Pharmaceuticals, Inc Bearish Trade. Flynn James E decreased Its Positionfdanewsalert.comFlynn James E filed with SEC a SC 13G/A form about Acura Pharmaceuticals, Inc. The form can be accessed here: 000119380516002575. As reported by Flynn James E, the filler decreased its stake in the stock by -400.00% for 1,025,641 shares.and more »
02/05/16 11:36 AMAcura Pharmaceuticals Incorporated (NASDAQ:ACUR) Sellers Covered 16.31% of Their Shorts - fdanewsalert.com - Acura Pharmaceuticals Incorporated (NASDAQ:ACUR) Sellers Covered 16.31% of Their Shortsfdanewsalert.comThe short interest to Acura Pharmaceuticals Incorporated's float is 0.54%. The stock increased 0.49% or $0.01 on February 4, hitting $2.05. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) has declined 53.93% since July 1, 2015 and is downtrending.and more »
02/01/16 06:28 PMStock Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc. Provides Development Update on Its LIMITX(TM) Abuse ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc. Provides Development Update on Its LIMITX(TM) Abuse ...Smarter AnalystAcura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that clinical testing of its lead LIMITX™ oral abuse deterrent drug candidate using the opioid hydromorphone HCl ...Acura Pharma (ACUR) to Commence LTX-04 Testing Under IND; Will Begin Phase 1 in Q116StreetInsider.comAcura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent TechnologyEIN News (press release)all 4 news articles »
02/01/16 03:11 PM4:11 pm Acura Pharma: Clinical testing of its lead LIMITX oral abuse deterrent drug candidate using the opioid LTX-04 is allowed to proceed under an IND the co filed with the FDA on Dec 30, 2015; expects top-line results in 2H16 -
11/10/15 05:26 AMAcura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse Deterrence Technology Innovation Award - [at noodls] - November 10, 2015 PALATINE, IL -- (Marketwired) -- 11/10/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse-deterrent drugs, announced that it received ...
11/05/15 05:04 AMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
11/04/15 04:50 PMACURA PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report -
11/04/15 03:48 PMAcura Pharmaceuticals Announces Third Quarter 2015 Financial Results - [at noodls] - Acura Pharmaceuticals Announces Third Quarter 2015 Financial Results
11/04/15 06:07 AMQ3 2015 Acura Pharmaceuticals Inc Earnings Release - After Market Close -
About Acura Pharmaceuticals

Acura Pharmaceuticals logoAcura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Delivery
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ACUR
  • CUSIP: 00509L70
Key Metrics:
  • Previous Close: $1.87
  • 50 Day Moving Average: $2.32
  • 200 Day Moving Average: $2.35
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $22.13M
  • Current Quarter EPS Consensus Estimate: $-1.01 EPS
Additional Links:
Acura Pharmaceuticals (NASDAQ:ACUR) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha